Neonatal Gentamicin Point of Care Genetic Testing (POCT)

What is Neonatal Point of Care Testing? 

Neonatal Point of Care Testing (POCT) is a new test that will be available for newborns with suspected sepsis.  It checks for a specific gene variant (M.1555A>G) that may increase their risk of permanent hearing loss from a common aminoglycoside antibiotic, gentamicin. This test ensures that babies receive the most effective treatment. 

What are the benefits of the Neonatal Point of Care Testing? 

The national roll out of point of care testing for neonatal gentamicin use is expected to deliver clinical benefits for babies and cost savings for NHS Scotland.   

Over a five-year period, the test could prevent heating loss in approximately 31 babies. 

The project is projected to save NHS Scotland a net cost saving of £199,236. Further analysis suggests that a broader social care savings could reach £14.5 million, made up from cost avoidance in additional education support and lifetime disability payments  

Click the links to find out about information for Clinicians and information for patients.